nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

26.12.2015 | Review Article

Epigenetic alternations and cancer chemotherapy response

verfasst von: Jin-Feng Lv, Lei Hu, Wei Zhuo, Cong-Min Zhang, Hong-Hao Zhou, Lan Fan

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Epigenetics, referring to alterations in gene expression without a change in nucleotide sequence in eukaryotes, mainly includes DNA methylation, miRNA and histone modification. In recent years, accumulating evidences have shown that epigenetic aberrations not only play important roles in the initiation and development of human cancers but also affect cancer chemotherapy response by altering the expression of key genes involved in the absorption, distribution, metabolism and excretion of drugs or those correlated with progression or severity of cancers. These epigenetic alterations, along with advanced detecting techniques, have great potential to be used as predictive and prognostic biomarkers for personalized therapy, especially in the field of cancer treatment. Here we provide an overview of recent findings on epigenetic alterations involved in cancer chemotherapy response, with the aim of promoting rational use of chemotherapy drugs in the clinic.

Verma M (2013) Cancer control and prevention: nutrition and epigenetics. Curr Opin Clin Nutr Metab Care 16:376–384PubMedCrossRef

Hojjat-Farsangi M (2015) Novel and emerging targeted-based cancer therapy agents and methods. Tumor Biol 36:543–556CrossRef

Evans WE, Johnson JA (2001) Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2:9–39PubMedCrossRef

Henikoff S, Matzke MA (1997) Exploring and explaining epigenetic effects. Trends Genet 13:293–295PubMedCrossRef

Liu MZ, McLeod HL, He FZ, Chen XP, Zhou HH, Shu Y (2014) Epigenetic perspectives on cancer chemotherapy response. Pharmacogenomics 15:699–715PubMedCrossRef

Sarkar S, Horn G, Moulton K (2013) Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci 14:21087–21113PubMedPubMedCentralCrossRef

Nana-Sinkam SP, Croce CM (2006) MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94:776–780CrossRef

Ivanov M, Kacevska M, Ingelman-Sundberg M (2012) Epigenomics and interindividual differences in drug response. Clin Pharmacol Ther 92:727–736PubMedCrossRef

Ma Y, Wang X, Jin H (2013) Methylated DNA and microRNA in body fluids as biomarkers for cancer detection. Int J Mol Sci 14:10307–10331PubMedPubMedCentralCrossRef

10.

Tang J, Xiong Y, Zhou HH, Chen XP (2014) DNA methylation and personalized medicine. J Clin Pharm Ther 39:621–627PubMedCrossRef

11.

Iwai N, Naraba H (2005) Polymorphisms in human pre-miRNAs. Biochem Biophys Res Commun 331:1439–1444PubMedCrossRef

12.

Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4:143–153PubMedCrossRef

13.

Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P (2009) The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41:178–186PubMedPubMedCentralCrossRef

14.

Chekhun VF, Kulik GI, Yurchenko OV (2006) Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett 231:87–93PubMedCrossRef

15.

Dejeux E, Rønneberg JA, Solvang H, Bukholm I, Geisler S, Aas T (2010) Research DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer 9:68PubMedPubMedCentralCrossRef

16.

Tsang WP, Kwok TT (2007) Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene 26:4877–4881PubMedCrossRef

17.

Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L (2006) ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 108:3881–3889PubMedPubMedCentralCrossRef

18.

Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113:2011–2021PubMed

19.

Gagnon JF, Bernard O, Villeneuve L, Têtu B, Guillemette C (2006) Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in Colon Cancer. Clin Cancer Res 12:1850–1858PubMedCrossRef

20.

Kim SJ, Kang HS, Jung SY, Min SY, Lee S, Kim SW (2010) Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues. J Mol Med 88:1123–1131PubMedCrossRef

21.

Nakamichi I, Tomita Y, Zhang B, Sugiyama H, Kanakura Y, Fukuhara S (2007) Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. Ann Hematol 86:557–564PubMedCrossRef

22.

Sieuwerts AM, Lyng MB, Meijer-van Gelder ME, de Weerd V, Sweep FC, Foekens JA (2014) Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor- positive breast cancer patients treated with tamoxifen in the advanced setting. Mol Oncol 8:1679–1689PubMedCrossRef

23.

Chen Y, Tang Y, Guo C (2012) Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol 83:1112–1126PubMedPubMedCentralCrossRef

24.

Raynal C, Pascussi JM, Leguelinel G (2010) Pregnane X receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer 9:46PubMedPubMedCentralCrossRef

25.

Grawenda AM, O’Neill E (2015) Clinical utility of RASSF1A methylation in human malignancies. Br J Cancer 113:372–381PubMedCrossRef

26.

Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A (2005) Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65:1141–1145PubMedCrossRef

27.

Gil EY, Jo UH, Jeong H, Whang YM, Woo OH, Cho KR (2012) Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. Int J Oncol 41:611–620PubMed

28.

Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Manegold C (2007) Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer 56:115–123PubMedCrossRef

29.

Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48:403–407PubMedCrossRef

30.

Pegg AE (2000) Repair of O⁶-alkylguanine by alkyltransferases. Mut Res/Rev Mut Res 462:83–100CrossRef

31.

Von Deimling A, Korshunov A, Hartmann C (2011) The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21:74–87CrossRef

32.

Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933–4938PubMedCrossRef

33.

Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871–1874PubMedCrossRef

34.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRef

35.

Everhard S, Kaloshi G, Crinière E, Benouaich-Amiel A, Lejeune J, Marie Y (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60:740–743PubMedCrossRef

36.

Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT (2009) Batchelor, MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 73:1509–1510PubMedPubMedCentralCrossRef

37.

Tuominen R, Jewell R, van den Oord JJ, Wolter P, Stierner U, Lindholm C (2015) MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. Int J Cancer 136:2844–2853PubMedCrossRef

38.

Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF (2006) Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci 103:8822–8827PubMedPubMedCentralCrossRef

39.

Scartozzi M, Bearzi I, Mandolesi A, Giampieri R, Faloppi L, Galizia E (2011) Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer 104:1786–1790PubMedPubMedCentralCrossRef

40.

Ebert MP, Tänzer M, Balluff B, Burgermeister E, Kretzschmar AK, Hughes DJ (2012) TFAP2E–DKK4 and chemoresistance in colorectal cancer. N Engl J Med 366:44–53PubMedCrossRef

41.

Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M (2009) DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 15:315–323PubMedCrossRef

42.

Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M (2008) Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13:91–104PubMedCrossRef

43.

Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E (2004) Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64:3807–3813PubMedCrossRef

44.

Chen B, Rao X, House MG, Nephew KP, Cullen KJ, Guo Z (2011) GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response. Cancer Lett 309:37–45PubMedCrossRef

45.

Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V (2013) Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 62:22–33PubMedCrossRef

46.

Sun S, Sun P, Wang C, Sun T (2014) Downregulation of microRNA-155 accelerates cell growth and invasion by targeting c-myc in human gastric carcinoma cells. Oncol Rep 32:951–956PubMed

47.

Nana-Sinkam SP, Croce CM (2012) Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93:98–104PubMedCrossRef

48.

Allen KE, Weiss GJ (2010) Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther 9:3126–3136PubMedCrossRef

49.

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257–2261PubMedPubMedCentralCrossRef

50.

Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM (2010) Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70:3606–3617PubMedPubMedCentralCrossRef

51.

Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E (2010) MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70:4528–4538PubMedCrossRef

52.

Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J (2011) Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286:19127–19137PubMedPubMedCentralCrossRef

53.

Echevarría-Vargas IM, Valiyeva F, Vivas-Mejía PE (2014) Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS One 9:e97094PubMedPubMedCentralCrossRef

54.

Chan JK, Blansit K, Kiet T (2014) The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol 132:739–744PubMedCrossRef

55.

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425–436PubMedPubMedCentral

56.

Donahue TR, Nguyen AH, Moughan J, Li L, Tatishchev S, Toste P (2014) Stromal MicroRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer. J Surg Oncol 110:952–959PubMedPubMedCentralCrossRef

57.

Kurashige J, Kamohara H, Watanabe M, Tanaka Y, Kinoshita K, Saito S (2012) Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol 106:188–192PubMedCrossRef

58.

Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon JH (2011) Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 17:3029–3038PubMedCrossRef

59.

Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8:1055–1066PubMedPubMedCentralCrossRef

60.

Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS (2012) Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther 11:2556–2565PubMedPubMedCentralCrossRef

61.

Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I (2011) The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 18:85–95PubMedCrossRef

62.

Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang B (2013) MiRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep 7:1579–1584PubMed

63.

Kovalchuk O, Filkowski J, Meservy J (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7:2152–2159PubMedCrossRef

64.

Tryndyak VP, Beland FA, Pogribny IP (2010) E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 126:2575–2583PubMed

65.

Chen J, Tian W, Cai H, He H, Deng Y (2012) Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 29:2527–2534PubMedCrossRef

66.

Alencar AJ, Malumbres R, Kozloski GA, Advani R, Talreja N, Chinichian S (2011) MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 17:4125–4135PubMedPubMedCentralCrossRef

67.

Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283:29897–29903PubMedPubMedCentralCrossRef

68.

Gan R, Yang Y, Yang X, Zhao L, Lu J, Meng QH (2014) Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther 21:290–296PubMedCrossRef

69.

Lu YZ, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C (2011) Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 286:42292–42302PubMedPubMedCentralCrossRef

70.

Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X (2008) MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283:31079–31086PubMedPubMedCentralCrossRef

71.

Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118:2603–2614PubMedCrossRef

72.

Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S (2011) Global microRNA expression profiling identifies miR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 6:20980CrossRef

73.

Chen J, Wang W, Zhang Y, Chen Y, Hu T (2014) Predicting distant metastasis and chemoresistance using plasma miRNAs. Med Oncol 31:1–7

74.

Mei Y, Gao C, Wang K, Cui L, Li W, Zhao X (2014) Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci 105:463–472PubMedPubMedCentralCrossRef

75.

Zhang T, Wang Q, Zhao D, Cui Y, Cao B, Guo L (2011) The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci 121:437–447PubMedCrossRef

76.

Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B (2010) Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 1:e105PubMedPubMedCentralCrossRef

77.

Mitamura T, Watari H, Wang L, Kanno H, Hassan MK, Miyazaki M (2013) Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2:e40PubMedPubMedCentralCrossRef

78.

Dong Z, Zhong Z, Yang L, Wang S, Gong Z (2014) MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett 343:249–257PubMedCrossRef

79.

Wang CJ, Stratmann J, Zhou ZG, Sun XF (2010) Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer 10:616PubMedPubMedCentralCrossRef

80.

Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693–705PubMedCrossRef

81.

Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150:12–27PubMedCrossRef

82.

Greer EL, Shi Y (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13:343–357PubMedPubMedCentralCrossRef

83.

Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J (2010) Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 10:788–795PubMedCrossRef

84.

Cai MY, Tong ZT, Zhu W, Wen ZZ, Rao HL, Kong LL (2011) H3K27me3 protein is a promising predictive biomarker of patients’ survival and chemoradioresistance in human nasopharyngeal carcinoma. Mol Med 17:1137PubMedPubMedCentral

85.

He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Guan XY (2009) Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer 9:461PubMedPubMedCentralCrossRef

86.

Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ (2006) Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 66:5582–5591PubMedCrossRef

87.

Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cellular Cheung-Lau G (2010) Histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 28:1358–1365PubMedPubMedCentralCrossRef

88.

Watanabe T, Morinaga S, Akaike M, Numata M, Tamagawa H, Yamamoto N (2012) The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery. Eur J Surg Oncol (EJSO) 38:1051–1057CrossRef

89.

Sakamoto K, Imamura T, Yano M, Yoshida H, Fujiki A, Hirashima Y, Hosoi H (2014) Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region. Blood Cancer J 4:e205PubMedPubMedCentralCrossRef

90.

Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner JL (2012) Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res 4:247PubMedPubMedCentral

91.

Toth M, Boros IM, Balint E (2012) Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells. Cancer Sci 103:659–669PubMedCrossRef

92.

Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L (2012) Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res 18:4070–4079PubMedPubMedCentralCrossRef

93.

Chang J, Varghese DS, Gillam MC, Peyton M, Modi B, Schiltz RL (2011) Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer 106:116–125PubMedPubMedCentralCrossRef

94.

McDonald KL, Rapkins RW, Olivier J (2013) The T genotype of the MGMT C> T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. Eur J Cancer 49:360–368PubMedCrossRef

95.

Rapkins RW, Wang F, Nguyen HTN (2015) The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro-oncology 17:1589–1598PubMedCrossRef

96.

Deng Y, Bai H, Hu H (2015) Rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression. Biochem Biophys Res Commun 458:321–327PubMedCrossRef

97.

Marschner N, Arnold D, Engel E, Hutzschenreuter U, Rauh J, Freier W (2008) Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Investig 118:2600

98.

Zhan X, Wu W, Han B (2012) Has-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population. J Clin Lab Anal 26:441–446PubMedCrossRef

99.

Boni V, Zarate R, Villa JC (2011) Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J 11:429–436PubMedCrossRef

100.

Thomadaki H, Talieri M, Scorilas A (2006) Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol Chem 387:1081–1086PubMedCrossRef

101.

Wang T, Huang B, Guo R (2015) A let-7b binding site SNP in the 3′-UTR of the Bcl-xL gene enhances resistance to 5-fluorouracil and doxorubicin in breast cancer cells. Oncol Lett 9:1907–1911PubMedPubMedCentral

102.

McDonald KL, Aw G, Kleihues P (2012) Role of biomarkers in the clinical management of glioblastomas: what are the barriers and how can we overcome them? Front Neurol 3:188PubMedPubMedCentral

103.

MDxHealth (2012) MDxHealth signs worldwide development and commercialization agreement with Merck KGaA for MGMT diagnostic test 5 July 2012

104.

Imanaka Y, Tsuchiya S, Sato F, Shimada Y, Shimizu K, Tsujimoto G (2011) MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 56:270–276PubMedCrossRef

105.

Fu X, Tian J, Zhang L, Chen Y, Hao Q (2012) Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 586:1279–1286PubMedCrossRef

106.

Zhao Z, Zhang L, Yao Q, Tao Z (2015) MiR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells. Cancer Gene Ther 22:108–114PubMedCrossRef

107.

Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, Theodorescu D, Ostenfeld MS, Hartmann A (2012) MiRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics 5:40PubMedPubMedCentralCrossRef

108.

De Cecco L, Berardi M, Sommariva M, Cataldo A, Canevari S, Mezzanzanica D (2013) Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation. PLoS One 8:e58849PubMedPubMedCentralCrossRef

109.

Li B, Chen H, Wu N (2014) Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance. Int J Gynecol Cancer 24(8):1381–1388PubMedCrossRef

110.

Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J (2012) MiR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 69:723–731PubMedCrossRef

111.

Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S (2008) MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 123:372–379PubMedCrossRef

112.

Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H (2012) MiR-34a predicts survival of Ewing’s sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 226:796–805CrossRef

113.

Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H (2011) Reduced miR-128 in breast tumor–initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 17:7105–7115PubMedCrossRef

114.

Tormo E, Pineda B, Serna E, Guijarro A, Ribas G, Fores J (2015) MicroRNA profile in response to doxorubicin treatment in breast cancer. J Cell Biochem 116:2061–2073PubMedCrossRef

115.

Yao YS, Qiu WS, Yao RY (2015) MiR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression. Oncol Rep 33:2504–2512PubMed

116.

Butrym A, Rybka J, Baczyńska D, Tukiendorf A, Kuliczkowski K, Mazur G (2015) Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients. Biomark Med 9:1–8CrossRef

117.

Xue J, Chi Y, Chen Y, Huang S, Ye X, Niu J (2015) MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. Oncogene 96:1–11

118.

Akçakaya P, Caramuta S, Åhlen J, Ghaderi M, Berglund E, Östman A (2014) MicroRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 111:2091–2102PubMedPubMedCentralCrossRef

Titel: Epigenetic alternations and cancer chemotherapy response
verfasst von: Jin-Feng Lv
Lei Hu
Wei Zhuo
Cong-Min Zhang
Hong-Hao Zhou
Lan Fan
Publikationsdatum: 26.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-015-2951-0

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Epigenetic alternations and cancer chemotherapy response

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy

Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer

Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo

Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie